Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis

Journal of Neuroscience Research

Volumn 91, Issue 4, 2013, Pages 585-592

  Potenza, Rosa Luisa ^a   Armida, Monica ^a   Ferrante, Antonella ^a   Pèzzola, Antonella ^a   Matteucci, Alessandra ^a   Puopolo, Maria ^a   Popoli, Patrizia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

A2ARs; Adenosine A2A receptors; ALS; Caffeine; SOD1G93A mice

Indexed keywords

ADENOSINE A2A RECEPTOR; CAFFEINE; COPPER ZINC SUPEROXIDE DISMUTASE; DRINKING WATER; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIAL GLUTAMATE TRANSPORTER 1; GLUTAMATE TRANSPORTER; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; LOG RANK TEST; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL CORD; SURVIVAL; WESTERN BLOTTING;

ADMINISTRATION, ORAL; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BODY WEIGHT; CAFFEINE; DISEASE MODELS, ANIMAL; LONGEVITY; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MOTOR SKILLS; RECEPTOR, ADENOSINE A2A; ROTAROD PERFORMANCE TEST; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 84873711954     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23185     Document Type: Article

References (49)

1. Albasanz JL, Perez S, Barrachina M, Ferrer I, Martin M. 2008. Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol 18: 211-219.
2. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson E, Zacharia L, Cracchiolo J, Shippy D, Tan J. 2006. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142: 941-952.
3. Beghi E, Pupillo E, Messina P, Giussani G, Chiò A, Zoccolella S, Moglia C, Corbo M, Logroscino G, EURALS Group. 2011. Coffee and amyotrophic lateral sclerosis: a possible preventive role. Am J Epidemiol 174: 1002-1008.
4. G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 79: 737-746.
5. Boillée S, Vande Velde C, Cleveland DW. 2006. ALS: a disease of motor neurons and their nonneuronal neighbours. Neuron 52: 39-59.
6. 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 83: 310-331.
7. Cleveland DW, Rothstein JD. 2001. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806-819.
8. Danbolt NC. 2001. Glutamate uptake. Prog Neurobiol 65: 1-105.
9. Danbolt NC, Pines G, Kanner BI. 1990. Purification and reconstitution of the sodium- and potassium-coupled glutamate transport glycoprotein from rat brain. Biochemistry 29: 6734-6740.
10. 2+ regulation in rat motoneurons during development. Cell Calcium 39: 237-246.
11. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci 24: 2905-2913.
12. Duru C, Simonin C, Richard F, Hincker P, Génin M, Charles P, Youssov K, Burnouf S, Azulay JP, Verny C, Tranchant C, Goizet C, Defebvre L, Sablonnière B, Rousseau M, Buée L, Amouyel P, Godefroy O, Dürr A, Bachoud-Lévi AC, Blum D, Krystkowiak P. 2010. C08 Caffeine is a modifier of age at onset in Huntington's disease. J Neurol Neurosurg Psychiatry 81: A18.
13. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. 1999. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83-133.
14. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. 2012. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 366: 1891-1904.
15. A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97: 505-519.
16. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai F, Sufit RL, Saddique T. 1994. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: 1772-1775.
17. 2A receptor antagonist. Eur J Pharmacol 406: 345-354.
18. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28: 1281-1291.
19. Keller AF, Gravel M, Kriz J. 2009. Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells. Glia 57: 1130-1142.
20. 2-induced apoptosis in primary cortical neurons. Neurochem Int 60: 466-474.
21. Lambrechts D, Poesen K, Fernández-Santiago R, Al-Chalabi A, Del Bo R, Van Vught PW Khan S, Marklund SL, Brockington A, van Marion I, Anneser J, Shaw C, Ludolph AC, Leigh NP, Comi GP, Gasser T, Shaw PJ, Morrison KE, Andersen PM, Van den Berg LH, Thijs V, Siddique T, Robberecht W, Carmeliet P. 2009. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet 46: 840-846.
22. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R, Niessen HG, Petri S, Pradat PF, Robberecht W, Ruegg M, Schwalenstöcker B, Stiller D, van den Berg L, Vieira F, von Horsten S. 2010. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler 11: 38-45.
23. 2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci Lett 417: 78-83.
24. 2A and Trk receptors. J Neurosci 26: 9250-9263.
25. Morozova N, Weisskopf MG, McCullough ML, Munger KL, Calle EE, Thun MJ, Ascherio A. 2008. Diet and amyotrophic lateral sclerosis. Epidemiology 19: 324-337.
26. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. 2007. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615-622.
27. 2A receptors after upper cervical (C2) spinal cord hemisection in adult rats. J Spinal Cord Med 30: 331-337.
28. 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J Neurochem 89: 152-156.
29. 2A receptors: implication for therapeutics. Curr Pharm Des 14: 1466-1467.
30. 2A receptors. Neurology 61(Suppl 6): S69-S71.
31. 2A receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal 3: 333-338.
32. 2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem 88: 1151-1158.
33. 2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol Biol Cell 18: 14-23.
34. Ribeiro JA, Sebastião AM. 2010. Caffeine and adenosine. J Alzheimers Dis 20(Suppl 1): S3-S15.
35. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van Den Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano EN, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown RHJr. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
36. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. 2000. Association of coffee and caffeine intake with the risk of Parkinson disease JAMA 283: 2674-2679.
37. Rosso A, Mossey J, Lippa CF. 2008. Caffeine: neuroprotective functions in cognition and Alzheimer's disease. Am J Alzheimers Dis Other Dementia 23: 417-422.
38. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. 1995. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73-84.
39. Seevaratnam R, Raha S, Tarnopolsky MA, Hamadeh MJ. 2009a. Coffee increases antioxidant enzyme capacity in the brain of male G93A mice, an animal model of amyotrophic lateral sclerosis (ALS). FASEB J 23:(Meeting Abstract Suppl):109.6.
40. Seevaratnam R, Raha S, Tarnopolsky MA, Hamadeh MJ. 2009b. Caffeine reduces motor performance and antioxidant enzyme capacity in the brain of female G93A mice, an animal model of amyotrophic lateral sclerosis (ALS). FASEB J 23:(Meeting Abstract Suppl):963.3.
41. 2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum. Brain Res 1283: 115-126.
42. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, Van Damme P, Rutten B, Man WY, De Mol M, Wyns S, Manka D, Vermeulen K, Van Den Bosch L, Mertens N, Schmitz C, Robberecht W, Conway EM, Collen D, Moons L, Carmeliet P. 2005. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85-92.
43. 2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J Neurochem 104: 279-286.
44. Thom E. 2007. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res 35: 900-908.
45. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. 2006. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762: 1068-1082.
46. 2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J 24: 587-598.
47. Wu T, Willett WC, Hankinson SE, Giovannucci E. 2005. Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in U.S. women. Diabetes Care 28: 1390-1396.
48. G93A ALS mouse. Exp Neurol 227: 287-295.
49. 2A receptor knockout mice with microarray profiling. Physiol Genom 37: 199-210.